Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kamie Williams

Nurse Practitioner Covington, LA Nurse Practitioner

NPI 1689205577 CMS profile 10856133

120 Lakeview Cir, Covington, LA 70433

Open in the dashboard

General payments

$15,466

583 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kamie Williams of Covington, LA is reported in the CMS Open Payments database as having received $15,466 across 583 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,444 104
2024 General $3,784 126
2023 General $2,626 116
2022 General $2,918 129
2021 General $3,694 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kamie Williams
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kamie Williams were reported at $2,444. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kamie Williams Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $3,694 $135 $40–$426 $132
2022 $2,918 $152 $48–$470 $149
2023 $2,626 $166 $54–$529 $160
2024 $3,784 $173 $55–$556 $164
2025 $2,444 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,675 60 payments
  2. Incyte Corporation $1,403 16 payments
  3. AstraZeneca Pharmaceuticals LP $1,179 40 payments
  4. Janssen Biotech, Inc. $820 35 payments
  5. Merck Sharp & Dohme Corporation $680 28 payments
  6. E.R. Squibb & Sons, L.L.C. $575 23 payments
  7. GlaxoSmithKline, LLC. $539 19 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $516 19 payments
  9. Eisai Inc. $445 24 payments
  10. Astellas Pharma US Inc $394 16 payments
  11. Other $7,240 303 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,328 571 payments
  2. Consulting Fee $1,125 1 payment
  3. Long term medical supply or device loan $698 7 payments
  4. Education $316 4 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,072 28 payments
  2. KEYTRUDA $662 27 payments
  3. OPDIVO $444 21 payments
  4. LIBTAYO $437 16 payments
  5. Lenvima $428 23 payments
  6. BESREMI $356 10 payments
  7. REBLOZYL $341 12 payments
  8. Doptelet $308 12 payments
  9. ONIVYDE $285 5 payments
  10. CALQUENCE $277 3 payments
  11. Other $11,001 520 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

453

Median for Nurse Practitioner: 389

Drug cost

$91,231

Median for Nurse Practitioner: $21,885

Branded share of claims

59.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Promacta Eltrombopag Olamine Brand 12 $82,022
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 128 $2,596
Oxycodone Hcl Generic 72 $1,478
Morphine Sulfate Er Morphine Sulfate Brand 37 $1,452
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 41 $1,295
Tamoxifen Citrate Generic 23 $981
Ondansetron Odt Ondansetron Brand 42 $478
Potassium Chloride Generic 17 $291
Anastrozole Generic 23 $193
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 11 $168

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 68 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $791
$791 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $171
  • Daiichi Sankyo Inc. $15
$186 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $123
$123 — —
Lenvima
  • Eisai Inc. $122
$122 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 68 with Patron

Records

583 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record